Waldenstrom Macroglobulinemia × Dexamethasone × Clear all A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Phase 2 Completed
7 enrolled 10 charts
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Phase 2 Completed
25 enrolled
VIWA-1
Phase 2 Recruiting
80 enrolled
Loncastuximab Tesirine in WM
Phase 2 Recruiting
36 enrolled
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Phase 3 Completed
202 enrolled
RAINBOW
Phase 2/3 Recruiting
148 enrolled
Ballondor
Phase 2 Recruiting
54 enrolled
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Phase 2 Completed
50 enrolled 11 charts
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
59 enrolled
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Phase 2 Completed
26 enrolled 14 charts
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
35 enrolled
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
CaRD
Phase 2 Completed
31 enrolled 10 charts
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Phase 1 Completed
25 enrolled
BOMB-THROW
Phase 2 Unknown
15 enrolled
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Phase 2 Completed
55 enrolled 6 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Phase 2 Completed
32 enrolled 7 charts
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Phase 1 Completed
48 enrolled 26 charts
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Phase 2 Completed
36 enrolled 7 charts
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Phase 1 Terminated
7 enrolled 8 charts
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Phase 2 Completed
23 enrolled 9 charts
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
9 enrolled
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
Phase 2 Withdrawn
BDR-WM
Phase 2 Completed
59 enrolled